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Abstract
Atrial fibrillation (AF) is estimated to affect 1%-2% of the population. It is increasing in prevalence and is
associated with excess mortality, considerable morbidity and hospitalisations. AF is responsible for a
significant and growing societal financial burden. Catheter ablation is an increasingly used therapeutic strategy
for the management of AF; however, some confusion exists among those caring for patients with this
condition about the role and optimal use of ablative treatments for AF. Our aim in this consensus statement is
to provide recommendations on the use of primary catheter ablation for AF in Australia, on the basis of
current evidence. Our consensus is that the primary indication for catheter ablation of AF is the presence of
symptomatic AF that is refractory or intolerant to at least one Class 1 or Class 3 antiarrhythmic medication. In
selecting patients for catheter ablation of AF, consideration should be given to the patient's age, duration of
AF, left atrial size and the presence of significant structural heart disease. Best results are obtained in younger
patients with paroxysmal AF, no structural heart disease and smaller atria. Ablation techniques for patients
with persistent AF are still undergoing evaluation. Discontinuation of warfarin or equivalent therapies is not
considered a sole indication for this procedure. After AF ablation, anticoagulation therapy is generally
recommended for all patients for at least 1-3 months. Discontinuation of warfarin or equivalent therapies after
ablation is generally not recommended in patients who have a CHADS 2 score (congestive heart failure,
hypertension, age ¿ 75 years, diabetes, 1 point each; prior stroke or transient ischaemic attack, 2 points) of ¿ 2.
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Position Statement
trial fibrillation (AF) affects 1%–2% of the popula-
tion, although this may be an underestimation, as
the condition is often asymptomatic. Factors that
predispose towards the risk of developing AF include
hypertension, valve disease, obesity, sleep apnoea, dia-
betes and renal disease.1 The prevalence of AF increases
with age — from rates lower than 0.5% among people
aged 40–50 years, to 5%–15% among those aged 80 years
— and is projected to double in the next 50 years, with the
increasing age of the general population.1 In 2009 there
were about 240 000 people with AF in Australia, which is a
conservative estimate of prevalence (1.1% of the popula-
tion).2 AF is associated with excess mortality, considerable
morbidity and hospitalisations. It is increasing in preva-
lence and is responsible for a significant and growing
societal financial burden.1,3,4
In recent times, a number of new medications and pro-
cedures to better manage this condition have been devel-
oped. Catheter ablation is an increasingly used therapeutic
strategy for the management of AF. National Heart Founda-
tion of Australia investigations suggested that confusion
exists among those caring for patients with this condition
about the role and optimal use of ablative treatments for AF.
Our aim in this consensus statement is to guide the use of
primary catheter ablation for AF in Australia on the basis of
current evidence. This is not a guideline, but rather general
recommendations to health care providers to assist them in
the care of these patients. Our intended audience is health
professionals in acute and primary care, including cardio-
logists, general practitioners and nurses.
The National Heart Foundation of Australia convened
an expert working group to evaluate the evidence and
provide guidance. Members of the expert working group
performed relevant literature searches, limited to evidence
from human studies published in English. This was com-
plemented by reference lists from reviews and personal
collections from the expert committee. Due to the limited
evidence in this area, these consensus recommendations
are largely based on expert opinion, and will likely evolve
as the evidence base informing the practice of AF ablation
grows. As a result, only one recommendation was graded
according to the National Health and Medical Research
Council (NHMRC) guidelines (Box).5 We consulted the
Board of the Cardiac Society of Australia and New Zealand
(CSANZ) and the CSANZ Electrophysiology and Pacing
Council during the development of this document, and the
CSANZ has endorsed the content.
Rationale for catheter ablation of AF
Currently the primary justification for catheter ablation of
AF is that of symptom control leading to improvement in
quality of life.1,6 Symptoms of AF can include palpitations,
breathlessness, fatigue, light-headedness, presyncope and
impaired exercise tolerance. A number of scoring systems
have been developed to standardise assessment of symp-
tom severity.1 In addition, there exist several as yet
unproven reasons to perform AF ablation, including
decreased stroke risk, decreased heart failure risk and
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• Atrial fibrillation (AF) is estimated to affect 1%–2% of 
the population. It is increasing in prevalence and is 
associated with excess mortality, considerable morbidity 
and hospitalisations. AF is responsible for a significant 
and growing societal financial burden.
• Catheter ablation is an increasingly used therapeutic 
strategy for the management of AF; however, some 
confusion exists among those caring for patients with this 
condition about the role and optimal use of ablative 
treatments for AF.
• Our aim in this consensus statement is to provide 
recommendations on the use of primary catheter 
ablation for AF in Australia, on the basis of current 
evidence.
• Our consensus is that the primary indication for catheter 
ablation of AF is the presence of symptomatic AF that is 
refractory or intolerant to at least one Class 1 or Class 3 
antiarrhythmic medication.
• In selecting patients for catheter ablation of AF, 
consideration should be given to the patient’s age, 
duration of AF, left atrial size and the presence of 
significant structural heart disease. Best results are 
obtained in younger patients with paroxysmal AF, no 
structural heart disease and smaller atria.
• Ablation techniques for patients with persistent AF are 
still undergoing evaluation.
• Discontinuation of warfarin or equivalent therapies is not 
considered a sole indication for this procedure.
• After AF ablation, anticoagulation therapy is generally 
recommended for all patients for at least 1–3 months. 
Discontinuation of warfarin or equivalent therapies after 
ablation is generally not recommended in patients who 
have a CHADS2 score (congestive heart failure, 
hypertension, age  75 years, diabetes, 1 point each; prior 
stroke or transient ischaemic attack, 2 points) of  2.
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improved survival.6 However, there is insufficient evidence
for AF ablation to be recommended for these indications at
this time.
Indications and patient selection
The primary indication for catheter ablation of AF is the
presence of symptomatic AF that is refractory or intolerant
to at least one Class 1 or Class 3 antiarrhythmic medica-
tion.6 However, it is recognised that in some highly select
clinical situations, it may be appropriate to perform cath-
eter ablation of AF as a first-line therapy. In some sympto-
matic patients who have heart failure and/or reduced
ejection fraction, ablation of AF is also appropriate.6 It
should be acknowledged that catheter ablation of AF is a
technically demanding procedure that may result in com-
plications. Patients should only undergo catheter ablation
of AF after careful assessment of the benefits and risks of
the procedure.
In selecting patients for catheter ablation of AF, consid-
eration should be given to the patient’s age, duration of AF,
left atrial size and the presence of significant structural
heart disease.1 The best results from AF ablation have been
reported in younger patients with paroxysmal AF and
without significant structural heart disease or marked atrial
enlargement.
Asymptomatic patients
In clinical practice, many patients with AF may be asymp-
tomatic but seek catheter ablation as an alternative to
long-term anticoagulation medication. Although retro-
spective studies have shown that discontinuation of warfa-
rin therapy after catheter ablation may be safe over
medium-term follow-up in some subsets of patients, there
is insufficient evidence to recommend AF ablation for this
indication.7,8 It is recognised that recurrence of sympto-
matic or asymptomatic AF may be found during long-term
follow-up after ablation.6 For these reasons, discontinua-
tion of warfarin or equivalent therapies is not a primary
ablation indication.
Techniques and end points
The pulmonary veins are the dominant source of triggers
initiating AF.9 In addition, in most patients with paroxys-
mal AF, these structures are responsible for the mainte-
nance of AF. As such, pulmonary vein ablation forms the
cornerstone for AF ablation.10 Complete electrical isolation
of these structures is considered essential. This strategy is
sufficient for the vast majority of patients with paroxysmal
AF. However, in patients with persistent AF, pulmonary
vein isolation alone may not be sufficient.11
Several other ablation strategies may be used in patients
with persistent AF, but their utility is still the subject of
ongoing evaluation.11 These include various forms of sub-
strate modification using either linear ablation (joining
anatomical structures) or electrogram-based strategies
(with a view to potentially identifying sources maintaining
AF). Regardless of the approach, there is an emphasis on
achieving complete lesions with electrophysiologically
proven end points.
In the sequence of the ablation, if a focal trigger is
identified outside a pulmonary vein at the time of an AF
ablation procedure, it should be targeted.6
Finally, if a patient has a history of typical atrial flutter,
ablation of the cavotricuspid isthmus is recommended.6
Technologies
The goal of AF ablation is to produce myocardial lesions
that bring about complete pulmonary vein isolation, or
that modify the arrhythmogenic substrate responsible for
re-entry.6 The success of the procedure is dependent on
reliably achieving lesions that include the full thickness of
the atrial myocardium.
The primary technique used at most AF ablation centres
is that of radiofrequency energy delivered via an irrigated
ablation catheter.6 In addition, three-dimensional catheter
location systems, which may reduce x-ray use and facilitate
the ablation procedure,12 are used in many laboratories.
The latter tool, while useful, is not an essential component
of the procedure.
A variety of alternative energy sources for ablation have
been evaluated. The main alternative available in Australia
is cryoablation. The reported results with this technique
have been variable.
Remote navigation has been under evaluation for some
time.6 The concept is extremely appealing for the operator
because it reduces radiation exposure and allows these
often lengthy procedures to be performed while seated.
Technologies developed to meet these objectives include
magnetic navigation systems or robotic controlled catheter
systems. As yet, there are no randomised multicentre
studies that have compared these technologies with man-
ual catheter manipulation, and their true role in AF abla-
tion remains uncertain.
Achieving full-thickness, complete and permanent
lesions remains challenging, despite significant techno-
logical advances. As a result, a repeat procedure may be
required in approximately one-third of patients.
When clinically indicated, AF ablation can also be
performed as part of an open cardiac surgery procedure
such as mitral valve surgery.1 Minimally invasive surgi-
cal approaches for ablation of AF are under ongoing
evaluation.
Prevention of thromboembolism
Careful attention to anticoagulation of patients before,
during and after AF ablation is critical to prevent thrombo-
embolism.6 Ablation causes substantial damage to the
endothelium, which may result in a nidus for thrombus
formation. Atrial myocardial function may be impaired for
several weeks after the reversion of AF. For these reasons,
patients undergoing ablation require anticoagulation ther-
apy during and after the procedure.
In general, we recommend adhering to the anticoagula-
tion guidelines that pertain to cardioversion of AF in
patients who present for AF ablation. In patients with a
CHADS2  (congestive heart failure, hypertension, age  75
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years, diabetes, 1 point each; prior stroke or transient
ischaemic attack, 2 points) score of  2 and/or persistent
AF, anticoagulation therapy is recommended for at least 3
weeks before ablation.13
In addition, TOE (transoesophageal echocardiography)
examination to exclude the presence of left atrial thrombus
is considered mandatory in patients with persistent AF
who are undergoing ablation.1,13 Indeed, many centres
undertake TOE in all patients undergoing AF ablation.
After AF ablation, anticoagulation therapy is generally
recommended for all patients for at least 1–3 months.
Discontinuation of warfarin or equivalent therapies after
ablation is generally not recommended in patients who
have a CHADS2 score of  2.
1,6,13 The CHA2DS2-VASc
score (congestive heart failure, hypertension, 1 point each;
age  75 years, 2 points; diabetes, 1 point; prior stroke or
transient ischaemic attack, 2 points; vascular disease, age
65–74 years, sex category [female], 1 point each) has been
proposed as an alternative to the CHADS2 score in an
attempt to identify a truly low-risk group with minimal risk
of thromboembolic events.1
Antiarrhythmic drugs and recurrences
Antiarrhythmic drugs are often used in the first months
after ablation.6,13 Early recurrences within the first 1–3
months after ablation are quite common and frequently
represent proarrhythmia resulting from the inflammation
caused by the procedure. These early recurrences do not
necessarily predict later recurrences. Approximately one-
third of patients will have a recurrence necessitating a
repeat procedure.14 There is a consensus that repeat abla-
tion procedures should, however, be delayed for a mini-
mum of 3 months, as early arrhythmias may settle
spontaneously.6,13
Finally, there is evidence that conditions associated
with an abnormal substrate, such as hypertension, sleep
apnoea and obesity, are associated with later recurrence
of arrhythmia.5 There is emerging evidence that treating
these modifiable risk factors in the general population
reduces the frequency of AF.1 Therefore, attention should
be given to modifiable risk factors in patients undergoing
ablation.
Success of ablation
A number of prospective randomised studies have com-
pared radiofrequency ablation with antiarrhythmic
drugs.15-18 These studies consistently show a highly signif-
icant increase in freedom from AF in the ablation arm, with
success rates of 70%–80%. Most of these studies included
follow-up of around 12 months and were conducted in a
younger group of patients with paroxysmal AF and with-
out advanced structural heart disease. Ablation techniques
and their role in patients with persistent AF are under
ongoing evaluation.11 Ablation for patients with long-
lasting persistent AF (at least 12 months of continuous AF)
has been less successful.
Clinical assessment and monitoring is routinely per-
formed after an AF ablation procedure.1,6 Follow-up
should include clinical evaluation every 3 to 6 months with
a 24-hour Holter monitor, and further evaluation using
Holter, event or electrocardiograhic monitoring if symp-
toms arise. In a research protocol, more extensive monitor-
ing would be required, including evaluation every 3 to 6
months with 7-day Holter monitors, 30-day event record-
ers and, more recently, implanted loop recorders.
Long-term outcomes
Recent studies at several centres have reported the long-
term outcomes of AF ablation with variable results. Most
of these studies provide data from mixed cohorts on the
duration of AF, the degree of structural heart disease and
the type of procedure performed. In addition, in most
cases, the data represent the early experience of the
centres. Overall, 5-year success rates ranged from 63% to
82%.19-21
Importantly, studies that have reported long-term fol-
low-up in patients with paroxysmal AF and with a struc-
turally normal heart show that most patients who are
arrhythmia-free 1 year after ablation remain arrhythmia-
free at 5 years after ablation.19
Complications
Several factors may contribute to the development of
complications in AF ablation. Important contributors
include a variety of patient factors related to the extent of
structural heart disease, procedural factors, and physician
and centre experience. In experienced centres, the risk of a
major complication is < 1%–2%.22 These serious complica-
tions include femoral vascular complications (such as large
haematoma), thromboembolic events, tamponade, valvu-
lar injury, pulmonary vein stenosis, phrenic or gastric nerve
injury, and atrio-oesophageal fistula (often fatal).
Conclusions
The expert consensus is that ablation of AF is an increas-
ingly used strategy, predominantly in symptomatic
National Heart Foundation of Australia recommendations on catheter ablation 
therapy for atrial fibrillation (AF) and levels of evidence and grades for 
recommendations*
1 The primary indication for catheter ablation of AF is the presence of symptomatic AF that is 
refractory or intolerant to at least one Class 1 or Class 3 antiarrhythmic medication. (Level I, 
grade A*)
2 In selecting patients for catheter ablation of AF, consideration should be given to the patient’s 
age, duration of AF, left atrial size and the presence of significant structural heart disease. Best 
results are obtained in younger patients with paroxysmal AF and without structural heart disease 
or marked atrial enlargement. (Consensus†)
3 Discontinuation of warfarin or equivalent therapies is not considered a sole indication for this 
procedure. (Consensus†)
4 After ablation of AF, anticoagulation therapy is generally recommended for all patients for at 
least 1–3 months. Discontinuation of warfarin or equivalent therapies after ablation is generally 
not recommended in patients who have a CHADS2 score of  2. (Consensus
†)
* Levels of evidence and grades for recommendations as defined by the National Health and Medical 
Research Council (NHMRC) ) in NHMRC levels of evidence and grades for recommendations for 
developers of clinical practice guidelines.5
† Due to the limited number of randomised clinical trials in this area, these consensus 
recommendations are largely based on expert opinion, and will likely evolve as the evidence base 
informing the practice of AF ablation grows. As a result, only one recommendation was graded 
according to NHMRC guidelines. ◆
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patients. Pulmonary vein isolation remains the corner-
stone of the strategy employed. The best results are
obtained in patients with paroxysmal AF, no structural
heart disease and smaller atria.
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